Qube Research & Technologies (QRT)’s Elevation Oncology ELEV Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio ELEV Stock Details ELEV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-67,377	Closed	-$24.7K	–	3676
2025 Q2	$24.7K	Buy	+67,377	New	+$22.5K	﹤0.01%	3238
2025 Q1	–	Sell	-24,217	Closed	-$13.6K	–	3581
2024 Q4	$13.6K	Buy	24,217 +13,623	+129%	+$8.04K	﹤0.01%	3217
2024 Q3	$6.36K	Sell	10,594 -121,304	-92%	-$180K	﹤0.01%	3074
2024 Q2	$356K	Sell	131,898 -10,827	-8%	-$40.8K	﹤0.01%	2248
2024 Q1	$732K	Buy	+142,725	New	+$462K	﹤0.01%	2329
2021 Q3	–	Sell	-24,255	Closed	-$329K	–	2346
2021 Q2	$329K	Buy	+24,255	New	+$300K	﹤0.01%	1518

Other funds holding ELEV

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Qube Research & Technologies (QRT)'s ELEV Position: Q3 2025 in Review

Qube Research & Technologies (QRT) sold out of Elevation Oncology (ELEV) in Q3 2025, closing a stake of 67,377 shares — an estimated $24.7K sold.

Qube Research & Technologies (QRT) first reported a position in ELEV in Q2 2021 and held it in 6 quarters. The position peaked at $732K in Q1 2024. 1 fund tracked by Wall St. Rank holds ELEV as of Q3 2025.

Qube Research & Technologies (QRT) reported no remaining Elevation Oncology position as of Q3 2025 after selling out during the quarter.
Qube Research & Technologies (QRT) sold 67,377 Elevation Oncology shares in Q3 2025, an estimated $24.7K.
Qube Research & Technologies (QRT) first reported a position in Elevation Oncology in Q2 2021 and held it in 6 quarters.
Qube Research & Technologies (QRT)'s Elevation Oncology position peaked at $732K in Q1 2024.
1 fund tracked by Wall St. Rank held Elevation Oncology as of Q3 2025.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q3 2025, filed 14 Nov 2025.